🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

RecruitingPhase 2Ages 18 Years - anyAllInstituto Nacional de Ciencias Medicas y Nutricio…
NCT07018622 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with cancer who receive platinum-based chemotherapy are at increased risk of kidney injury caused by these drugs. This form of toxicity can lead to treatment delays, dose reductions, or permanent discontinuation of chemotherapy, all of which can negatively impact cancer outcomes and increase patient morbidity. Despite the clinical significance, there are currently no effective strategies to prevent platinum-induced kidney damage. Existing preventive measures-such as hydration, mannitol use, and magnesium supplementation-are limited and not always effective. This clinical trial investigates whether a type of medication known as a Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor, specifically dapagliflozin, can protect the kidneys from damage during platinum-based chemotherapy in patients with solid tumors. Researchers believe that blocking SGLT2 in the kidney may reduce toxicity

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Signed informed consent form * Diagnosis of a solid tumor requiring a platinum-based chemotherapy regimen (cisplatin or carboplatin) * Expected survival \> 4 months * ECOG performance status 0-2 Exclusion Criteria: * History of nephrectomy * History of kidney transplant * Concurrent use of known nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cyclophosphamide, ifosfamide, methotrexate) * Type 1 diabetes mellitus * Poorly controlled type 2 diabetes (HbA1c \> 8% or fasting glucose \> 200 mg/dL in the past month) * Active glomerulopathy * Prior use of SGLT2 inhibitors or current indication for their use * eGFR \< 20 ml/min/1.73 m² * Active urinary tract infection * Unresolved obstructive uropathy * Participation in another clinical trial * History of recurrent genitourinary infections
💊

What it tests

  • Dapagliflozin 10 MG Oral Tablet
  • Placebo Oral Tablet
📍

Where

1 site
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
México, Mexico
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy